New IMBRUVICA® (ibrutinib) Data in Fixed-Duration Combination Regimen Presented at EHA 2022 Shows Deep, Durable Response at Three Years in Untreated Chronic Lymphocytic Leukemia

/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new and updated results from the Phase 2 CAPTIVATE study evaluating...

Related Keywords

Spain ,Vienna ,Wien ,Austria ,Barcelona ,Comunidad Autonoma De Cataluna ,Sant Pau ,Carol Moreno ,Christie Corbett ,None Of The Janssen Pharmaceutical Companies ,Abbvie Company ,Janssen Biotech Inc ,European Hematology Association Annual Congress ,European Hematology Association ,Drug Administration ,Janssen Research Development ,Janssen Pharmaceutical Companies ,Janssen Pharmaceutical Companies Of Johnson ,Exchange Commission ,Autonomous University Of Barcelona ,Companies Of Johnson ,Johnson ,National Comprehensive Cancer Network ,Hematology Association ,Annual Congress ,Consultant Hematologist ,Autonomous University ,Janssen Biotech ,Year Follow Up Data ,Based Combination Regimen ,Previously Untreated Patients ,Confidence Interval ,Guided Cohort ,Thenew England Journal ,Medicine Evidence ,National Comprehensive Cancer ,Cardiac Failure ,Sudden Death ,Primary Malignancies ,Lysis Syndrome ,Fetal Toxicity ,Pharmaceutical Companies ,Infectious Diseases ,Private Securities Litigation Reform Act ,Janssen Research ,Annual Report ,Note Regarding Forward Looking ,Quarterly Reports ,Duration Ibrutinib ,First Line Treatment ,Chronic Lymphocytic ,Small Lymphocytic Lymphoma ,Year Follow Up From ,Hematology Association Annual ,Translational Analyses ,Duration Ibrutinib Venetoclax ,Chronic Lymphocytic Leukemia ,Clinical Practice Guidelines ,Comprehensive Cancer ,Accessed June ,Janssen Oncology ,